Core Viewpoint - The company reported a significant decline in net profit and revenue for the third quarter, primarily due to decreased gross margins in its main product lines, particularly sea cucumbers and testing kits [5]. Financial Performance - The net profit attributable to shareholders decreased by 51.43% year-on-year, mainly due to a decline in gross margin [5]. - Revenue from sea cucumbers dropped by 62.56%, attributed to reduced sales and a shift in production strategy [5]. - Revenue from testing kits fell by 76.13%, largely due to the loss of a significant order from a key customer [5]. - The net profit excluding non-recurring gains and losses decreased by 38.31% year-on-year, reflecting similar trends as the overall net profit [5]. - The net cash flow from operating activities increased by 37.99% compared to the same period last year, driven by higher sales in the seafood processing business [5]. Shareholder Information - The company confirmed that there were no changes in the number of shareholders or significant shareholders participating in stock lending activities [6]. Product Development - The company's wholly-owned subsidiary, Aiveke Biotechnology Co., Ltd., received regulatory approval for a new medical device, the NT-proBNP testing kit, which is expected to enhance its product line in clinical diagnostics [10][11]. - The impact of this new product on the company's performance remains uncertain, as it has not yet commenced production and its market performance will depend on various factors [9][11].